Hope for Long COVID sufferers

Plus more health news |

Email not displaying correctly? View it in your browser.

Long COVID research is in its 'most hopeful' phase yet By Jamie Ducharme Health Correspondent Over the past three years, thousands of studies on Long COVID have been published. But very few have led to tangible benefits for the millions of people living with this often-debilitating condition. It’s too soon to make any concrete promises, but researchers expect that to change. “In the short history of studying this disease, this is probably the most hopeful moment we’ve ever had,” researcher Christoph Thaiss told me for a new story. Within the past couple months, two large studies—one co-authored by Thaiss—have found potential biomarkers that could make it easier to diagnose Long COVID. That’s big on its own, since lots of people are misdiagnosed or entirely missed by physicians who don’t have much experience in Long COVID. But it also opens the doors to potential treatments, because understanding what causes a condition makes it that much easier to get it under control. READ MORE Share This Story

What Else to Read Why Better Community Engagement is Key to The Future of Clean Tech By Justin Worland Engaging communities makes projects more likely to succeed in the short term and makes them more sustainable investments in the long run. Read More » This Is the Best Time of Day to Work Out, According to Science By Jamie Ducharme If you want to optimize your workouts to get the widest range of benefits, you might want to try exercising in the morning. (Originally published in 2019.) Read More » What We Know About Leaky Gut Syndrome By Elaine K. Howley Leaky gut is a condition in which the lining of the intestines become inflamed, damaged, or irritated. Read More » Why Spicy Food Makes Your Nose Run—and Why It's Great for You By Markham Heid A plant compound called capsaicin has an ability to combat pain. (Originally published in 2019.) Read More » 5 Ways to Keep Your Brain Sharp As You Age By Matt Fuchs An aging mind isn't a weak one. (Originally published in 2021.) Read More »

ONE LAST READ Ozempic maker Novo Nordisk is too big for Denmark Novo Nordisk, the Denmark-based maker of blockbuster drugs Ozempic and Wegovy, is a very big fish in very small pond. As Stephen Wilmot reports in the Wall Street Journal, Novo's shares are overwhelming the stock index of Danish companies, creating a peculiar a set of problems for Danish investors. Read More »

If you were forwarded this and want to sign up to receive it daily, click here. Today's newsletter was written by Jamie Ducharme and Oliver Staley, and edited by Oliver.

Want more from TIME? Sign up for our other newsletters. Subscribe to TIME

TIME may receive compensation for some links to products and services in this email. Offers may be subject to change without notice.   Connect with TIME via Facebook | Twitter | Newsletters       UNSUBSCRIBE     PRIVACY POLICY     YOUR CALIFORNIA PRIVACY RIGHTS   TIME Customer Service, P.O. Box 37508, Boone, IA 50037-0508   Questions? Contact health@time.com   Copyright © 2023 TIME USA, LLC. All rights reserved.